167 related articles for article (PubMed ID: 27964881)
1. Bivalent SIRT1 inhibitors.
Wang J; Zang W; Liu J; Zheng W
Bioorg Med Chem Lett; 2017 Jan; 27(2):180-186. PubMed ID: 27964881
[TBL] [Abstract][Full Text] [Related]
2. Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
Galli U; Mesenzani O; Coppo C; Sorba G; Canonico PL; Tron GC; Genazzani AA
Eur J Med Chem; 2012 Sep; 55():58-66. PubMed ID: 22835719
[TBL] [Abstract][Full Text] [Related]
3. N(epsilon)-Modified lysine containing inhibitors for SIRT1 and SIRT2.
Huhtiniemi T; Suuronen T; Lahtela-Kakkonen M; Bruijn T; Jääskeläinen S; Poso A; Salminen A; Leppänen J; Jarho E
Bioorg Med Chem; 2010 Aug; 18(15):5616-25. PubMed ID: 20630764
[TBL] [Abstract][Full Text] [Related]
4. Hit-to-lead optimization on aryloxybenzamide derivative virtual screening hit against SIRT.
Yagci S; Gozelle M; Kaya SG; Ozkan Y; Aksel AB; Bakar-Ates F; Dundar Y; Eren G
Bioorg Med Chem; 2021 Jan; 30():115961. PubMed ID: 33360574
[TBL] [Abstract][Full Text] [Related]
5. A bicyclic pentapeptide-based highly potent and selective pan-SIRT1/2/3 inhibitor harboring N
Li R; Yan L; Sun X; Zheng W
Bioorg Med Chem; 2020 Apr; 28(7):115356. PubMed ID: 32067892
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
Sakai T; Matsumoto Y; Ishikawa M; Sugita K; Hashimoto Y; Wakai N; Kitao A; Morishita E; Toyoshima C; Hayashi T; Akiyama T
Bioorg Med Chem; 2015 Jan; 23(2):328-39. PubMed ID: 25515955
[TBL] [Abstract][Full Text] [Related]
7. Cyclic peptide-based potent and selective SIRT1/2 dual inhibitors harboring N
Chen D; Zheng W
Bioorg Med Chem Lett; 2016 Nov; 26(21):5234-5239. PubMed ID: 27707605
[TBL] [Abstract][Full Text] [Related]
8. Novel thiourea-based sirtuin inhibitory warheads.
Zang W; Hao Y; Wang Z; Zheng W
Bioorg Med Chem Lett; 2015 Aug; 25(16):3319-24. PubMed ID: 26081291
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in inhibitors of sirtuin1/2: an update and perspective.
Zhou Z; Ma T; Zhu Q; Xu Y; Zha X
Future Med Chem; 2018 Apr; 10(8):907-934. PubMed ID: 29642711
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Advantage of SIRT2-Selective versus pan-SIRT1-3 Inhibitors.
Hong JY; Fernandez I; Anmangandla A; Lu X; Bai JJ; Lin H
ACS Chem Biol; 2021 Jul; 16(7):1266-1275. PubMed ID: 34139124
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Biological Evaluation of 8-Mercapto-3,7-Dihydro-1
Han H; Li C; Li M; Yang L; Zhao S; Wang Z; Liu H; Liu D
Molecules; 2020 Jun; 25(12):. PubMed ID: 32549218
[TBL] [Abstract][Full Text] [Related]
12. Carprofen analogues as sirtuin inhibitors: enzyme and cellular studies.
Mellini P; Carafa V; Di Rienzo B; Rotili D; De Vita D; Cirilli R; Gallinella B; Provvisiero DP; Di Maro S; Novellino E; Altucci L; Mai A
ChemMedChem; 2012 Nov; 7(11):1905-8. PubMed ID: 24155041
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, in-vitro evaluation and molecular docking studies of novel indole derivatives as inhibitors of SIRT1 and SIRT2.
Manjula R; Gokhale N; Unni S; Deshmukh P; Reddyrajula R; Srinivas Bharath MM; Dalimba U; Padmanabhan B
Bioorg Chem; 2019 Nov; 92():103281. PubMed ID: 31561106
[TBL] [Abstract][Full Text] [Related]
14. The 2.5 Å crystal structure of the SIRT1 catalytic domain bound to nicotinamide adenine dinucleotide (NAD+) and an indole (EX527 analogue) reveals a novel mechanism of histone deacetylase inhibition.
Zhao X; Allison D; Condon B; Zhang F; Gheyi T; Zhang A; Ashok S; Russell M; MacEwan I; Qian Y; Jamison JA; Luz JG
J Med Chem; 2013 Feb; 56(3):963-9. PubMed ID: 23311358
[TBL] [Abstract][Full Text] [Related]
15. Discovery of bicyclic pyrazoles as class III histone deacetylase SIRT1 and SIRT2 inhibitors.
Therrien E; Larouche G; Nguyen N; Rahil J; Lemieux AM; Li Z; Fournel M; Yan TP; Landry AJ; Lefebvre S; Wang JJ; MacBeth K; Heise C; Nguyen A; Besterman JM; Déziel R; Wahhab A
Bioorg Med Chem Lett; 2015 Jun; 25(12):2514-8. PubMed ID: 25971769
[TBL] [Abstract][Full Text] [Related]
16. How much successful are the medicinal chemists in modulation of SIRT1: A critical review.
Kumar A; Chauhan S
Eur J Med Chem; 2016 Aug; 119():45-69. PubMed ID: 27153347
[TBL] [Abstract][Full Text] [Related]
17. Current advances in the synthesis and antitumoral activity of SIRT1-2 inhibitors by modulation of p53 and pro-apoptotic proteins.
Botta G; De Santis LP; Saladino R
Curr Med Chem; 2012; 19(34):5871-84. PubMed ID: 22998567
[TBL] [Abstract][Full Text] [Related]
18. Cyclic Tripeptide-based Potent and Selective Human SIRT5 Inhibitors.
Jiang Y; Zheng W
Med Chem; 2020; 16(3):358-367. PubMed ID: 31161996
[TBL] [Abstract][Full Text] [Related]
19. Virtual screening approach of sirtuin inhibitors results in two new scaffolds.
Kokkonen P; Kokkola T; Suuronen T; Poso A; Jarho E; Lahtela-Kakkonen M
Eur J Pharm Sci; 2015 Aug; 76():27-32. PubMed ID: 25936698
[TBL] [Abstract][Full Text] [Related]
20. Identification of benzofuran-3-yl(phenyl)methanones as novel SIRT1 inhibitors: binding mode, inhibitory mechanism and biological action.
Wu J; Li Y; Chen K; Jiang H; Xu MH; Liu D
Eur J Med Chem; 2013 Feb; 60():441-50. PubMed ID: 23318905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
